Terms ending in 2039
Roche Sequencing Solutions, Inc.
Every in-force patent on Roche Sequencing Solutions, Inc.'s record whose computed term ends in 2039, whoever holds it now. Soonest term end first, then patent number.
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
| Patent | Title | Holder | Status | Expires | Confidence |
|---|---|---|---|---|---|
| US 12,571,050 | Method of Predicting Response to Therapy by Assessing Tumor Genetic Heterogeneity In force · High confidence | Roche Sequencing Solutions, Inc. | In force | High confidence | |
| US 11,345,955 | Hybridization-Extension-Ligation Strategy for Generating Circular Single-Stranded DNA Libraries In force · High confidence | Kapa Biosystems, Inc. | In force | High confidence | |
| US 11,519,026 | Methods for Removal of Adaptor Dimers from Nucleic Acid Sequencing Preparations In force · High confidence | Roche Sequencing Solutions, Inc. | In force | High confidence | |
| US 11,821,041 | Non-Invasive Test to Predict Recurrence of Colorectal Cancer In force · High confidence | Roche Sequencing Solutions, Inc. | In force | High confidence | |
| US 11,708,566 | DP04 Polymerase Variants In force · High confidence | Roche Sequencing Solutions, Inc. | In force | High confidence | |
| US 11,519,037 | Non-Invasive Test to Predict Response to Therapy in Colorectal Cancer Patients In force · High confidence | Roche Sequencing Solutions, Inc. | In force | High confidence | |
| US 12,188,079 | Determining the Sequence of a Double-Stranded Target Nucleic Acid by Employing a Terminal Transferase, Forming a Linear Joint Molecule, and Sequencing in One Direction In force · High confidence | Roche Sequencing Solutions, Inc. | In force | High confidence | |
| US 11,548,911 | Cleavable Linker for Peptide Synthesis In force · High confidence | Roche Sequencing Solutions, Inc. | In force | High confidence | |
| US 11,603,565 | A System for Identification of Antigens Recognized by T Cell Receptors Expressed on Tumor Infiltrating Lymphocytes In force · High confidence | Roche Sequencing Solutions, Inc. | In force | High confidence | |
| US 11,691,141 | Devices for Sample Analysis Using Epitachophoresis In force · High confidence | Roche Sequencing Solutions, Inc. | In force | High confidence | |
| 6 more term ends in 2039 · Pro | |||||
10 of 16 patents shown. Soonest term end first, then patent number.
Pro members see all 16.
15 of these are in force and held by Roche Sequencing Solutions, Inc..
Updated Nov 22, 2026 · includes USPTO assignment data published Nov 21, 2026, status data published Nov 22, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.